TY - JOUR
T1 - Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice
AU - Recuenco, Frances C.
AU - Takano, Ryo
AU - Chiba, Shiori
AU - Sugi, Tatsuki
AU - Takemae, Hitoshi
AU - Murakoshi, Fumi
AU - Ishiwa, Akiko
AU - Inomata, Atsuko
AU - Horimoto, Taisuke
AU - Kobayashi, Yoshiyasu
AU - Horiuchi, Noriyuki
AU - Kato, Kentaro
N1 - Funding Information:
This study was supported by Grants-in-Aids for Young Scientists, and Scientific Research on Innovative Areas (3308) from the Ministry of Education, Culture, Science, Sports, and Technology (MEXT) and for Research on global health issues from the Ministry of Health, Labour, and Welfare of Japan, by Bio-oriented Technology Research Advancement Institution (BRAIN), by the Naito Foundation, and by the Programme to Disseminate Tenure Tracking System from the Japan Science and Technology Agency (JST). We would also like to thank Dr. Maria Shirley Herbas of the NRCPD, Obihiro University of Agriculture and Veterinary Medicine for providing training on tissue handling and collection.
Publisher Copyright:
© 2014 Recuenco et al.
PY - 2014/12/11
Y1 - 2014/12/11
N2 - Background: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blood-brain barrier, raising concerns that their use as a treatment for malaria could lead to cerebral malaria (CM), a severe complication of the disease. In this work, the authors look into the effects of the administration of λ-carrageenan to the development and severity of CM in BALB/c mice, a relatively non-susceptible model, during infection with the ANKA strain of Plasmodium berghei. Methods: Five-week-old female BALB/c mice were infected with P. berghei intraperitoneally. One group was treated with λ-carrageenan (PbCGN) following the 4-day suppressive test protocol, whereas the other group was not treated (PbN). Another group of healthy BALB/c mice was similarly given λ-carrageenan (CGN) for comparison. The following parameters were assessed: parasitaemia, clinical signs of CM, and mortality. Brain and other vital organs were collected and examined for gross and histopathological lesions. Evans blue dye assays were employed to assess blood-brain barrier integrity. Results: Plasmodium berghei ANKA-infected BALB/c mice treated with λ-carrageenan died earlier than those that received no treatment. Histopathological examination revealed that intracerebral haemorrhages related to CM were present in both groups of infected BALB/c mice, but were more numerous in those treated with λ-carrageenan than in mock-treated animals. Inflammatory lesions were also observed only in the λ-carrageenan-treated mice. These observations are consistent with the clinical signs associated with CM, such as head tilt, convulsions, and coma, which were observed only in this group, and may account for the earlier death of the mice. Conclusion: The results of this study indicate that the administration of λ-carrageenan exacerbates the severe brain lesions and clinical signs associated with CM in BALB/c mice infected with P. berghei ANKA.
AB - Background: There is an urgent need to develop and test novel compounds against malaria infection. Carrageenans, sulphated polysaccharides derived from seaweeds, have been previously shown to inhibit Plasmodium falciparum in vitro. However, they are inflammatory and alter the permeability of the blood-brain barrier, raising concerns that their use as a treatment for malaria could lead to cerebral malaria (CM), a severe complication of the disease. In this work, the authors look into the effects of the administration of λ-carrageenan to the development and severity of CM in BALB/c mice, a relatively non-susceptible model, during infection with the ANKA strain of Plasmodium berghei. Methods: Five-week-old female BALB/c mice were infected with P. berghei intraperitoneally. One group was treated with λ-carrageenan (PbCGN) following the 4-day suppressive test protocol, whereas the other group was not treated (PbN). Another group of healthy BALB/c mice was similarly given λ-carrageenan (CGN) for comparison. The following parameters were assessed: parasitaemia, clinical signs of CM, and mortality. Brain and other vital organs were collected and examined for gross and histopathological lesions. Evans blue dye assays were employed to assess blood-brain barrier integrity. Results: Plasmodium berghei ANKA-infected BALB/c mice treated with λ-carrageenan died earlier than those that received no treatment. Histopathological examination revealed that intracerebral haemorrhages related to CM were present in both groups of infected BALB/c mice, but were more numerous in those treated with λ-carrageenan than in mock-treated animals. Inflammatory lesions were also observed only in the λ-carrageenan-treated mice. These observations are consistent with the clinical signs associated with CM, such as head tilt, convulsions, and coma, which were observed only in this group, and may account for the earlier death of the mice. Conclusion: The results of this study indicate that the administration of λ-carrageenan exacerbates the severe brain lesions and clinical signs associated with CM in BALB/c mice infected with P. berghei ANKA.
KW - BALB/c mouse
KW - Cerebral malaria
KW - Intracerebral haemorrhage
KW - Plasmodium berghei ANKA
KW - λ-carrageenan
UR - http://www.scopus.com/inward/record.url?scp=84928808612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928808612&partnerID=8YFLogxK
U2 - 10.1186/1475-2875-13-487
DO - 10.1186/1475-2875-13-487
M3 - Article
C2 - 25495520
AN - SCOPUS:84928808612
SN - 1475-2875
VL - 13
JO - Malaria Journal
JF - Malaria Journal
IS - 1
M1 - 487
ER -